|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-3-2
|
|
pubmed:abstractText |
Therapies of advanced melanoma patients with interleukin-2 (IL-2) and cytotoxic lymphocytes have produced interesting results, but a larger diffusion of these treatments is limited by the severe side effects due to IL-2 systemic infusion. A strictly regional administration of IL-2 and cells by an isolation perfusion (IP) in extracorporeal circulation (ECC) for the treatment of regional melanoma metastases could improve tolerability and efficacy of this specific modality of immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
61-70
|
|
pubmed:dateRevised |
2007-7-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7834457-Adult,
pubmed-meshheading:7834457-Aged,
pubmed-meshheading:7834457-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:7834457-Extracorporeal Circulation,
pubmed-meshheading:7834457-Feasibility Studies,
pubmed-meshheading:7834457-Female,
pubmed-meshheading:7834457-Follow-Up Studies,
pubmed-meshheading:7834457-Humans,
pubmed-meshheading:7834457-Immunotherapy, Adoptive,
pubmed-meshheading:7834457-Infusions, Intravenous,
pubmed-meshheading:7834457-Interleukin-2,
pubmed-meshheading:7834457-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:7834457-Leg,
pubmed-meshheading:7834457-Leukapheresis,
pubmed-meshheading:7834457-Lymphocyte Count,
pubmed-meshheading:7834457-Melanoma,
pubmed-meshheading:7834457-Middle Aged,
pubmed-meshheading:7834457-Remission Induction,
pubmed-meshheading:7834457-Skin Neoplasms,
pubmed-meshheading:7834457-Survival Rate
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
